Literature DB >> 10334395

Slow progression of juvenile metachromatic leukodystrophy 6 years after bone marrow transplantation.

P Kapaun1, R W Dittmann, B Granitzny, W Eickhoff, H Wulbrand, E Neumaier-Probst, A Zander, A Kohlschüetter.   

Abstract

Metachromatic leukodystrophy refers to a group of genetic neurologic diseases caused by deficiencies of the enzyme arylsulfatase A and the resulting accumulation of sulfatides in white matter. Bone marrow transplantation has been advocated as a treatment in an attempt to correct the enzyme deficiency. Such a transplant was performed in 1991 in a 16-year-old girl with a form of late juvenile metachromatic leukodystrophy caused by a homozygous P426L mutation in the arylsulfatase A gene. Engraftment was prompt and resulted in constant enzymatic normalization of circulating lymphocytes. The elevated urinary excretion of sulfatides remained unaffected. Clinical findings up until transplantation consisted of gait disturbances, impairment of cognitive functioning, and deterioration in school performance over several years. During a 6-year follow-up period, the patient's condition was subject to major fluctuations but, on the whole, findings showed slow neurologic and neurophysiologic deterioration. The clinical course observed after bone marrow transplantation probably more or less reflects the natural course expected in this form of late-onset metachromatic leukodystrophy.

Entities:  

Mesh:

Year:  1999        PMID: 10334395     DOI: 10.1177/088307389901400402

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  5 in total

Review 1.  Metachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature.

Authors:  Asif Mahmood; Jay Berry; David A Wenger; Maria Escolar; Magdi Sobeih; Gerald Raymond; Florian S Eichler
Journal:  J Child Neurol       Date:  2009-12-28       Impact factor: 1.987

2.  Secretion of phosphomannosyl-deficient arylsulphatase A and cathepsin D from isolated human macrophages.

Authors:  Nicole Muschol; Ulrich Matzner; Stephan Tiede; Volkmar Gieselmann; Kurt Ullrich; Thomas Braulke
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

3.  Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy.

Authors:  M Solders; D A Martin; C Andersson; M Remberger; T Andersson; O Ringdén; G Solders
Journal:  Bone Marrow Transplant       Date:  2014-05-05       Impact factor: 5.483

4.  Haematopoietic stem cell transplantation does not retard disease progression in the psycho-cognitive variant of late-onset metachromatic leukodystrophy.

Authors:  Nicholas J Smith; Robert E Marcus; Barbara J Sahakian; Narinder Kapur; Timothy M Cox
Journal:  J Inherit Metab Dis       Date:  2010-11-16       Impact factor: 4.982

5.  Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report.

Authors:  Alexander A Boucher; Weston Miller; Ryan Shanley; Richard Ziegler; Troy Lund; Gerald Raymond; Paul J Orchard
Journal:  Orphanet J Rare Dis       Date:  2015-08-07       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.